Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
CPT: Pharmacometrics & Systems Pharmacology|November 17, 2022
An introduction to causal inference for pharmacometriciansJames A Rogers, Hugo Maas, Alejandro Pérez PitarchCPT: Pharmacometrics & Systems Pharmacology|January 26, 2019
Modeling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by AfatinibRonald Niebecker, Hugo Maas, Alexander Staab, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2002
Model of chemotherapy-induced myelosuppression with parameter consistency across drugsLena E Friberg, Anja Henningsson, Hugo Maas, et al.Journal of Cardiovascular Pharmacology and Therapeutics|April 27, 2018
Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal FunctionJack L Martin, Habib Esmaeili, Raymond C Manuel, et al.Clinical Pharmacokinetics|May 20, 2019
A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired PatientsDaniel Moj, Hugo Maas, André Schaeftlein, et al.Thrombosis and Haemostasis|August 17, 2018
Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical TrialsHugo Maas, Savion Gropper, Fenglei Huang, et al.Thrombosis and Haemostasis|December 5, 2017
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous ThromboembolismJacqueline M L Halton, Anne-Caroline Picard, Ruth Harper, et al.The New England Journal of Medicine|September 3, 2013
Dabigatran versus warfarin in patients with mechanical heart valvesJohn W Eikelboom, Stuart J Connolly, Martina Brueckmann, et al.Pageof 1